Get notified when VKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $29.35 Per Share (new) — The offering price is $35.00, but pro forma as adjusted net tangible book value per share after the offering is only $5.65, resulting in immediate dilution of $29.35 per share for new investors.
- Concurrent Convertible Note Offering Adds $225m In Debt (new) — The company is concurrently offering $225M of convertible notes, which will add significant indebtedness and potential future dilution upon conversion.
Viking Therapeutics prices $275M stock offering at $35/share; concurrent $225M convertible note offering
Filed September 25, 2026 · ~1 min read
Key Changes
-
high
Viking Therapeutics is selling 7,857,143 shares at $35.00 per share, raising $275.0M gross, with net proceeds to the company of $258.2M.
The Offering verify on EDGAR → -
high
Concurrently, the company is offering $225M of 2.00% convertible senior notes due 2032, with an option for an additional up to $33.75M.
The Offering verify on EDGAR → -
medium
Net proceeds from both offerings are earmarked for clinical development of VK2735 and VK3019, plus general corporate purposes.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade VKTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 25, 2026 · How we verify